follitropin alfa
Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
... prefilled follitropin alfa pen among both patients and nurses ...prefilled follitropin alfa pen or to the reusable follitropin beta pen ...tropin alfa pen found the pen very easy ...
7
Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
... for follitropin alfa, the first recombinant-human follicle stim- ulating hormone (r-hFSH) approved, to be quantified and filled by mass, with a small variance of only ±2% and no more with a bioassay with a ...
7
Ovulation induction with minimal dose of follitropin alfa: a case series study
... This retrospective case series study was based on data from case reports of women with anovulatory infertility (mainly due to PCOS) who were treated with follitropin alfa (GONAL-f ® , Merck Serono S.A. - ...
7
Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment
... visit. Follitropin alfa was self-administered subcutaneously daily using the rede- signed ...of follitropin alfa, which was dosed according to the standard clinical practice (and within the ...
14
A redesigned follitropin alfa pen injector for infertility: results of a market research study
... redesigned follitropin alfa pen; 46% (n = 13) thought it was “much” or “somewhat” easier to teach patients to use the redesigned follitropin alfa pen, and 50% (n = 14) considered it was ...
17
A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility
... biosimilar follitropin alfa is available only as single-use, fixed-dose, prefilled pens in contrast to the originator, which is available as multidose vials and prefilled ...
7
A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection
... In Brazil, the acquisition cost of r-hFSH is about 40-50% more expensive than the urinary menotropins; until now, this was an argument that supported the choice of urinary menotropins for COH. However, in our analysis, ...
11
A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology
... Approximately 70% of the current study population was aged ≥35 years. This might be expected as there is a general trend for delayed childbearing in Western soci- eties [19], with many couples seeking ART for this rea- ...
8
Multicenter, noninterventional, post-marketing surveillance study to evaluate dosing of recombinant human follicle-stimulating hormone using the redesigned follitropin alfa pen in women undergoing ovulation induction
... This noninterventional, post-marketing surveillance study found that monofollicular or bifollicular development was achieved in 71% of the women who received r-hFSH using the redesigned follitropin alfa pen ...
6
Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague-Dawley rats
... Follitropin alfa RFF biopotency was determined using the traditional Steelman-Pohley hCG augmentation assay, which measures ovarian hypertrophy resulting from exog- enous FSH treatments of immature female ...
6
Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
... whether follitropin alfa (GONAL-f (R)), as lyophilized powder for reconstitution or solution from the GONAL-f (R) (filled-by-mass [FbM]) Prefilled Pen, could be used to reconstitute Pergoveris TM ...
5
Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study
... (follitropin alfa, Theramex UK Ltd) is an r- hFSH developed as a biosimilar to Gonal-f®, administered subcutaneously by the use of a multidose, reusable, semi- automated pen injector and approved by the ...
9
Recombinant follitropin alfa/lutropin alfa in fertility treatment
... over follitropin alpha in controlled ovarian hyper- stimulation for IVF in terms of live birth rate per ...to follitropin alpha in an unselected IVF population. The use of follitropin alpha is ...
13
Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
... follitropin alfa, Merck Serono, Feltham, UK), providing another rhFSH option for ART patients and their caregivers. Manufactured using Chinese hamster ovary cells transfected with the human ...
10
<p>A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany</p>
... Within the limitations of this study, our results suggest that in comparison to Biosimilar 1 and Biosimilar 2, the Originator is associated with a higher live birth rate and a lower cost per live birth in Germany. This ...
13
Phase I, two-way, crossover study to demonstrate bioequivalence and to compare safety and tolerability of single-dose XM17 vs Gonal-f® in healthy women after follicle-stimulating hormone downregulation
... The systemic and local tolerability of XM17 was also similar to that of approved follitropin alfa [13]. Head- ache was the most frequently reported AE for both XM17 and Gonal-f ® . Except for mild pain on ...
8
Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients
... who presented stable hemoglobin levels of 10–11.5 g/dL with standard liquid EPO alfa product (EPREX, Cilag AG, Schaffhausen, Switzerland) treatment for at least 12 weeks. All patients had adequate dialysis by a ...
9
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
... The JFR-002 is a long-term, prospective, observational study to evaluate efficacy and safety of ERT with agalsi- dase alfa for 5 years. Treatment with ERT and obser- vation for all patients for the study period ...
9
The safety profile of drotrecogin alfa (activated)
... In ENHANCE (Extended Evaluation of Recombinant Human Activated Protein C, drotrecogin alfa [activated]), a single-arm, open-label trial [12], a total of 2,378 adult patients with severe sepsis received DrotAA. ...
8
4795.pdf
... offer support and relief to those who needed it. The category “Non-Fiction—Lesbian” highlighted Love Between Women, by Charlotte Wolff (1971); Lesbian/Woman, by Del Martin and Phyllis Lyon (1972); Sappho Was a Right-On ...
318